James A Simon Selected Research

Ospemifene

1/2019	Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
1/2019	Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
1/2018	Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
6/2013	Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
4/2013	One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James A Simon Research Topics

Disease

25	Psychological Sexual Dysfunctions (Sexual Arousal Disorder) 02/2022 - 07/2005
17	Atrophy 01/2019 - 10/2008
12	Dyspareunia 01/2019 - 10/2011
11	Breast Neoplasms (Breast Cancer) 05/2022 - 09/2008
9	Nausea 01/2022 - 12/2012
7	Headache (Headaches) 01/2022 - 06/2014
6	Leiomyoma (Uterine Fibroids) 10/2021 - 01/2018
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 09/2008
5	Endometriosis 10/2021 - 01/2004
5	Menorrhagia 10/2021 - 11/2018
5	Metrorrhagia (Spotting) 01/2020 - 01/2003
4	Dizziness (Lightheadedness) 01/2020 - 12/2012
4	Pain (Aches) 01/2020 - 01/2017
4	Syncope (Fainting) 01/2020 - 01/2015
4	Uterine Hemorrhage (Uterine Bleeding) 07/2014 - 01/2003
4	Osteoporosis 02/2013 - 11/2002
3	Neoplasms (Cancer) 05/2022 - 01/2018
3	Flushing 01/2022 - 11/2019
3	Pelvic Pain 10/2021 - 01/2017
3	Amenorrhea 01/2021 - 01/2003
3	Hypotension (Low Blood Pressure) 01/2020 - 11/2019
3	Hemorrhage 01/2020 - 01/2003
3	Venous Thromboembolism 01/2018 - 07/2014
3	Hot Flashes 01/2017 - 05/2003
3	Sleepiness 01/2015 - 12/2012
2	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 04/2012
2	Body Weight (Weight, Body) 01/2022 - 11/2017
2	Weight Loss (Weight Reduction) 10/2019 - 11/2017
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018 - 10/2011
2	Dysmenorrhea (Menstrual Pain) 01/2018 - 01/2017
2	Metabolic Bone Diseases (Osteopenia) 08/2011 - 02/2006
1	Thromboembolism 05/2022
1	Stroke (Strokes) 05/2022
1	Endometrial Neoplasms (Endometrial Cancer) 05/2022
1	Coronary Disease (Coronary Heart Disease) 05/2022
1	Hyperpigmentation 01/2022
1	Injection Site Reaction 01/2022
1	Vertigo (Positional Vertigo) 01/2020
1	Orthostatic Hypotension (Postural Hypotension) 11/2019
1	Overweight 10/2019
1	Triple Negative Breast Neoplasms 01/2018
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Myocardial Infarction 01/2018
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018
1	Vascular Diseases (Vascular Disease) 01/2018
1	Pruritus (Itching) 05/2017
1	Virilism (Virilization) 01/2017

Drug/Important Bio-Agent (IBA)

19	Estrogens (Estrogen)FDA Link 05/2022 - 05/2003
13	Estradiol (Delestrogen)FDA LinkGeneric 05/2022 - 07/2011
11	Testosterone (Sustanon)FDA Link 05/2022 - 07/2005
11	flibanserin (BIMT 17)IBA 02/2022 - 12/2012
10	Hormones (Hormone)IBA 01/2021 - 05/2003
7	elagolixIBA 10/2021 - 01/2017
6	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2021 - 01/2004
6	Progestins (Progestagens)IBA 01/2018 - 05/2003
6	TX-004HRIBA 09/2017 - 12/2016
5	bremelanotideIBA 01/2022 - 11/2019
5	Selective Estrogen Receptor Modulators (SERM)IBA 01/2019 - 05/2003
5	OspemifeneIBA 01/2019 - 04/2013
4	Norethindrone Acetate (Norlutate)FDA LinkGeneric 01/2021 - 01/2003
3	AndrogensIBA 12/2021 - 07/2009
3	TabletsIBA 01/2020 - 07/2011
3	Ethanol (Ethyl Alcohol)IBA 01/2020 - 11/2019
3	Dehydroepiandrosterone (DHEA)IBA 01/2018 - 03/2010
3	Capsules (Microcapsules)IBA 09/2017 - 01/2017
3	Diphosphonates (Bisphosphonates)IBA 04/2010 - 11/2002
2	Pharmaceutical PreparationsIBA 11/2019 - 11/2010
2	Serotonin Receptor Agonists (Serotonin Receptor Agonist)IBA 10/2019 - 06/2014
2	Serotonin 5-HT2 Receptor AntagonistsIBA 01/2019 - 11/2017
2	Serotonin 5-HT1 Receptor AgonistsIBA 01/2019 - 11/2017
2	Analgesics (Analgesic Drugs)IBA 01/2018 - 01/2017
2	Raloxifene Hydrochloride (Evista)FDA Link 09/2014 - 08/2011
2	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 07/2014 - 01/2003
2	Conjugated (USP) Estrogens (Premarin)FDA Link 07/2014 - 01/2003
2	Progesterone FDA LinkGeneric 07/2014 - 07/2009
2	Alendronate (Alendronate Sodium)FDA LinkGeneric 02/2006 - 11/2002
1	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2022
1	linzagolixIBA 10/2021
1	relugolixIBA 10/2021
1	opigolixIBA 10/2021
1	Hemin (Panhematin)FDA Link 01/2021
1	Vaginal Creams, Foams, and Jellies (Vaginal Tablet)IBA 01/2020
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2020
1	Serotonin (5 Hydroxytryptamine)IBA 01/2019
1	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 11/2018
1	ulipristalIBA 01/2018
1	ulipristal acetate FDA Link 01/2018
1	CreatinineIBA 01/2018
1	LipidsIBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	Estrogen ReceptorsIBA 01/2018
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2018
1	Aromatase InhibitorsIBA 01/2018
1	RAD1901IBA 01/2017
1	Paroxetine (Paxil)FDA LinkGeneric 09/2014

Therapy/Procedure

25	Therapeutics 12/2021 - 01/2003
3	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2018 - 01/2003
1	Aftercare (After-Treatment) 12/2021
1	Activities of Daily Living (ADL) 01/2019